Welcome to our dedicated page for Oscar Health SEC filings (Ticker: OSCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oscar Health, Inc. (NYSE: OSCR) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret complex documents. Oscar identifies itself in these filings as a healthcare technology company whose Class A common stock trades on the New York Stock Exchange under the symbol OSCR. Through its reports, investors can review how the company structures its health insurance operations, technology initiatives, and capital markets activities.
Oscar’s annual reports on Form 10-K and quarterly reports on Form 10-Q provide overviews of its Individual & Family health plans, health technology solutions under the +Oscar brand, risk factors, and detailed financial statements. These core filings typically include information on revenues, medical costs, selling, general, and administrative expenses, membership metrics, and key non-GAAP measures such as Adjusted EBITDA, along with management’s discussion of business drivers.
The company’s current reports on Form 8-K offer more targeted updates. Recent 8-K filings describe quarterly financial results, reaffirmed guidance, and capital structure actions such as the issuance of 2.25% Convertible Senior Subordinated Notes due 2030, related capped call transactions, and an exchange agreement involving 7.25% Convertible Senior Notes due 2031. Other 8-Ks detail amendments to investment agreements, the planned termination of a revolving credit facility in connection with a notes offering, and changes to executive employment agreements and compensation structures.
Investors can also use this page to access information on convertible debt terms, events of default, subordination provisions, and potential share dilution from note conversion, all of which are described in Oscar’s indentures and related exhibits. Stock Titan’s AI summaries help explain the implications of these filings, highlight key sections of lengthy documents, and surface important items such as changes in guidance, financing transactions, and governance-related disclosures. This makes it easier to understand how Oscar’s regulatory filings relate to its health insurance operations, technology platform, and long-term financial strategy.
OSCR filed a Form 144 notice for a proposed sale of common stock. The filing lists 105,300 shares to be sold with an aggregate market value of $1,585,133.55, through Morgan Stanley Smith Barney LLC, on or about 11/12/2025. The shares trade on the NYSE.
The securities to be sold were acquired on 11/12/2025 via an exercise of options under a registered plan, with payment in cash. Shares outstanding were 229,010,000 as of the figures provided. The filing also reports sales in the past three months by a named seller: 286,182 shares on 11/11/2025 for $4,369,512.63, and 395,000 shares on 09/22/2025 for $7,280,995.50.
Form 144 is a notice of proposed sale under Rule 144 and does not itself effect a sale; it discloses intent and relevant limits and timing.
Oscar Health (OSCR) filed a Form 144 indicating a proposed sale of 286,182 common shares, with an aggregate market value of $4,369,512.63. The filing lists Morgan Stanley Smith Barney LLC as broker, an approximate sale date of 11/11/2025, and the NYSE as the exchange.
The shares were acquired on 11/11/2025 via exercise of options under a registered plan, paid in cash. As a reference figure, the filing notes 229,010,000 shares outstanding. In the past three months, Mario T Schlosser reported a sale of 395,000 shares on 09/22/2025 for $7,280,995.50.
Oscar Health (OSCR) reported a Q3 2025 net loss and higher revenue. Total revenue was $2,985,984 thousand, up from $2,423,482 thousand a year ago, driven by premium growth and investment income. Net loss attributable to the company was $137,450 thousand, or $0.53 per diluted share, compared with a $54,596 thousand loss in Q3 2024.
Cash and cash equivalents were $2,148,865 thousand, and long‑term debt rose to $686,294 thousand, reflecting the issuance of $410,000 thousand 2.25% convertible senior subordinated notes due 2030 and existing 7.25% notes due 2031. The company recorded risk adjustment transfer payable of $1,771,305 thousand as of September 30, 2025, after increasing estimates based on updated market data.
Oscar ended the quarter with approximately 2.1 million effectuated members and closed acquisitions of INSXCloud, IHC Specialty Benefits, and Healthinsurance.org in May 2025. Subsequent events included note conversions and exchanges, and the purchase of capped calls for $34,440 thousand to mitigate conversion-related dilution on the 2030 notes.
Oscar Health (OSCR) entered an Exchange Agreement with Dragoneer, allowing exchanges of up to $250,000,000 principal of 7.25% convertible senior notes due 2031 through December 14, 2025. On November 5, 2025, Dragoneer exchanged $187,500,000 of these notes for 23,273,179 Class A shares, and the company was relieved of future interest payments on the exchanged debt.
The Agreement also provides for up to $17.8 million of additional consideration, payable in shares and/or cash, pursuant to its terms and conditions. As of November 5, 2025, debt covenants in the 2031 notes Investment Agreement were extinguished, and the company’s $410,000,000 2.25% convertible senior subordinated notes due 2030 ceased to be subordinated to the 2031 notes.
Separately, the company furnished a press release announcing financial results for the quarter ended September 30, 2025 as Exhibit 99.1.
Oscar Health (OSCR) reported a Form 4 showing a director received 1,004 deferred stock units on 10/09/2025, calculated using the Class A closing price of $20.54. Following the transaction, the reporting person beneficially owned 3,749 derivative securities. Under the plan, these units are 100% vested on grant and will be settled for cash or shares, at the company’s discretion, within 45 days of termination of service, a change in control, death, or disability. The director elected DSUs in lieu of cash retainer payments.
Oscar Health (OSCR) reported a director equity transaction. A director received 1,034 deferred stock units on October 9, 2025 at $20.54 per unit under the company’s Amended and Restated Deferred Compensation Plan for Directors, electing DSUs in lieu of a cash retainer. Each DSU represents the right to receive one share of Class A common stock and is 100% vested on the grant date. DSUs will be settled for cash or shares, at the company’s discretion, within 45 days of the earliest of termination of service, a change in control, death, or disability. Following this grant, the reporting person held 4,136 derivative securities directly.
Oscar Health (OSCR) Form 4: A director acquired 2,555 deferred stock units on October 9, 2025, reported with transaction code A. The price of $20.54 reflects the Class A common stock closing price used to calculate the number of units under the company’s director deferred compensation plan. Each unit represents a right to receive one share of Class A common stock. Following this grant, the director beneficially owned 63,142 derivative securities, held directly. The units are 100% vested on the grant date and will be settled in cash or shares at the company’s discretion upon specified triggering events.
Oscar Health insider filings show option exercise and share sale by Mario Schlosser. Mr. Schlosser exercised 555,165 vested stock options with a $6.36 exercise price on 09/22/2025, creating the right to 555,165 Class A shares. Concurrently he converted and sold 395,000 Class A shares in multiple transactions at a weighted average price of $18.43 to cover the exercise cost and tax withholding, leaving him with 501,148 Class A shares beneficially owned. Certain remaining shares are held indirectly in family dynasty trusts over which he disclaims beneficial ownership except for any pecuniary interest.
Oscar Health, Inc. (OSCR) submitted a Form 144 notice reporting a proposed sale of 395,000 common shares through Morgan Stanley Smith Barney LLC on the NYSE with an approximate aggregate market value of $7,280,995.50. The filing shows the shares were acquired and will be sold on 09/22/2025 via exercise of options under a registered plan and payment was in cash. The filer reports 223,044,000 shares outstanding for the issuer and indicates no other securities were sold in the past three months. The notice includes the standard representation that the seller is unaware of undisclosed material adverse information.
Oscar Health, Inc. filed an 8-K reporting execution of an Indenture dated September 18, 2025 between the company and U.S. Bank Trust Company, National Association as trustee. The filing includes the form of certificate for 2.25% Convertible Senior Subordinated Notes due 2030 (Exhibit A to Exhibit 4.1) and a form of Capped Call Confirmation. The submission also contains the cover page interactive data file embedded in the inline XBRL document. The filing is signed by R. Scott Blackley, Chief Financial Officer.